Multifocal Intraocular Lens Provides Favorable Contrast Sensitivity in Trial

Photo Essay From Hospital. Clinique De La Roseraie, In Paray Le Monial, France. Department Of Surgery, Operating Room. Surgical Intervention Of The Cataract. Intervention Of Microsurgery Of A Duration From 10 To 15 Minutes. (Photo By BSIP/UIG Via Getty Images)
A patient survey indicated a preference for the lens to the control.

This article is part of Ophthalmology Advisor’s conference coverage from the 2021 meeting of American Society of Cataract and Refractive Surgery (ASCRS), held in Las Vegas from July 23 to 27, 2021. The team at Ophthalmology Advisor will be reporting on a variety of research presented by the cataract and refractive surgery experts at ASCRS. Check back for more from the ASCRS 2021 Meeting.


A segmented multifocal intraocular lens (IOL) design did not provide a statistically significant difference in contrast sensitivity of <0.20 log units, compared with the control, according to findings presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, held in Las Vegas from July 23 to 27. However, on a scale of 1 to 5, patients ranked the likelihood to choose the same lens again as 4.16, compared with 3.66 for the control (P <.0001).

Researchers compared the bilateral implantation results of the SBL-3 multifocal IOL (Lenstec Inc.) to that of a control lens. Clinical trial enrollment was randomized (2:1 randomization plan), and participants were evaluated up to 1 year postoperative. 

The study reported the mean difference in binocular contrast sensitivity between the SBL-3 and the control under phototopic conditions with glare as 0.169cpd; without glare as 0.185cpd; under mesotopic conditions with glare as 0.1442cpd; and without glare as 0.178cpd (P <.05).

The mean total visual disturbance score was 2.15 for the SBL-3 and 1.74 for the control (P =.034), on a scale of 0 to 10. The mean total spectacle independence score for the SBL-3 was 1.28 and 2.78 for the control (P <.0001). 

Disclosure: The study author declared affiliations with the biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.  

Visit Ophthalmology Advisor’s conference section for complete coverage of the ASCRS 2021 meeting and more.



Loden J. Clinical study results of a new segmented multifocal IOL: Overall results from all 18 investigational sites for “quality” of vision only. Presented at: 2021 ASCRS Annual Meeting; July 23-27, 2021; Las Vegas, NV. Poster 78313.